Whitehawk Therapeutics, Inc. Income Statement
WHWK|8 years of annual SEC 10-K data (FY2018-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 8 fiscal years. All figures from audited SEC 10-K filings.
Whitehawk Therapeutics, Inc. reported $26M in revenue and $64M in net loss for FY2025. Revenue has grown at a 52.8% compound annual rate over the past 7 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -0.35 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $26.0M | $24.4M | $14.0M | $14.0M | $14.6M | $0 | $20.2M | $1.3M |
| Cost of Revenue | $3.0M | $2.8M | $1.3M | $0 | - | - | - | - |
| SG&A Expense | $36.7M | $44.5M | $40.2M | $18.5M | $2.1M | $9.8M | $13.5M | $9.2M |
| R&D Expense | $51.0M | $48.9M | $32.7M | $19.7M | $15.0M | $12.8M | $17.9M | $12.1M |
| Operating Income | -$67.5M | -$71.9M | -$62.7M | -$111.2M | -$2.5M | -$24.4M | -$11.2M | -$21.4M |
| Interest Expense | - | - | $230.0K | $665.0K | $815.0K | - | - | - |
| Income Tax | $0 | $0 | $0 | $2.0K | $2.0K | - | - | - |
| Net Income | -$63.7M | -$65.8M | -$60.5M | -$110.1M | -$3.5M | -$23.3M | -$10.4M | -$21.4M |
| EPS (Basic) | -$2.36 | -$2.44 | -$2.69 | -$12.41 | - | - | - | - |
| EPS (Diluted) | -$2.36 | -$2.44 | -$2.69 | -$12.41 | -$1.76 | -$0.57 | -$0.31 | -$1.03 |
| Shares Outstanding | 24.7M | 24.6M | 24.4M | 2.5M | 2.5M | 40.6M | 40.6M | 27.1M |
| Operating Margin | -259.6% | -295.4% | -447.7% | -794.4% | -17.5% | - | -55.5% | -1604.1% |
| Profit Margin | -245.1% | -270.0% | -432.2% | -786.4% | -23.8% | - | -51.6% | -1605.0% |